CN101838252A - 2-正丁基-5-取代氨基苯并呋喃及其制备方法 - Google Patents
2-正丁基-5-取代氨基苯并呋喃及其制备方法 Download PDFInfo
- Publication number
- CN101838252A CN101838252A CN201010184543A CN201010184543A CN101838252A CN 101838252 A CN101838252 A CN 101838252A CN 201010184543 A CN201010184543 A CN 201010184543A CN 201010184543 A CN201010184543 A CN 201010184543A CN 101838252 A CN101838252 A CN 101838252A
- Authority
- CN
- China
- Prior art keywords
- compound
- formula
- solvent
- reaction
- consumption
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims description 21
- -1 2- normal-butyl-5-substituted amino benzofuran Chemical class 0.000 title abstract description 13
- ZQTNQVWKHCQYLQ-UHFFFAOYSA-N dronedarone Chemical compound C1=CC(OCCCN(CCCC)CCCC)=CC=C1C(=O)C1=C(CCCC)OC2=CC=C(NS(C)(=O)=O)C=C12 ZQTNQVWKHCQYLQ-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229960002084 dronedarone Drugs 0.000 claims abstract description 16
- 150000001875 compounds Chemical class 0.000 claims description 47
- 238000006243 chemical reaction Methods 0.000 claims description 27
- 239000002904 solvent Substances 0.000 claims description 24
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 23
- 239000003960 organic solvent Substances 0.000 claims description 17
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 12
- 230000035484 reaction time Effects 0.000 claims description 12
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 claims description 10
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 claims description 10
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 claims description 10
- 239000000543 intermediate Substances 0.000 claims description 8
- 238000010992 reflux Methods 0.000 claims description 8
- 235000017550 sodium carbonate Nutrition 0.000 claims description 7
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 7
- FCSKOFQQCWLGMV-UHFFFAOYSA-N 5-{5-[2-chloro-4-(4,5-dihydro-1,3-oxazol-2-yl)phenoxy]pentyl}-3-methylisoxazole Chemical compound O1N=C(C)C=C1CCCCCOC1=CC=C(C=2OCCN=2)C=C1Cl FCSKOFQQCWLGMV-UHFFFAOYSA-N 0.000 claims description 6
- 239000002841 Lewis acid Substances 0.000 claims description 6
- 230000010933 acylation Effects 0.000 claims description 6
- 238000005917 acylation reaction Methods 0.000 claims description 6
- 150000007517 lewis acids Chemical class 0.000 claims description 6
- 229910000033 sodium borohydride Inorganic materials 0.000 claims description 6
- 239000012279 sodium borohydride Substances 0.000 claims description 6
- 125000002252 acyl group Chemical group 0.000 claims description 5
- GXPHKNHECGMZNQ-UHFFFAOYSA-N carbonochloridoyl 2-phenylacetate Chemical compound C1(=CC=CC=C1)CC(=O)OC(=O)Cl GXPHKNHECGMZNQ-UHFFFAOYSA-N 0.000 claims description 5
- 239000003153 chemical reaction reagent Substances 0.000 claims description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 4
- 150000001263 acyl chlorides Chemical class 0.000 claims description 4
- 239000003513 alkali Substances 0.000 claims description 4
- 125000003368 amide group Chemical group 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 claims description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 4
- 229910052794 bromium Inorganic materials 0.000 claims description 4
- 229960004424 carbon dioxide Drugs 0.000 claims description 4
- 235000011089 carbon dioxide Nutrition 0.000 claims description 4
- 230000018044 dehydration Effects 0.000 claims description 4
- 238000006297 dehydration reaction Methods 0.000 claims description 4
- 125000004989 dicarbonyl group Chemical group 0.000 claims description 4
- 230000008030 elimination Effects 0.000 claims description 4
- 238000003379 elimination reaction Methods 0.000 claims description 4
- YWGHUJQYGPDNKT-UHFFFAOYSA-N hexanoyl chloride Chemical compound CCCCCC(Cl)=O YWGHUJQYGPDNKT-UHFFFAOYSA-N 0.000 claims description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- 239000011707 mineral Substances 0.000 claims description 4
- 235000010755 mineral Nutrition 0.000 claims description 4
- 239000001301 oxygen Substances 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 claims description 3
- 239000012346 acetyl chloride Substances 0.000 claims description 3
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 3
- 235000015320 potassium carbonate Nutrition 0.000 claims description 3
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 claims description 2
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims description 2
- 229910015900 BF3 Inorganic materials 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 2
- 125000004744 butyloxycarbonyl group Chemical group 0.000 claims description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
- 238000009833 condensation Methods 0.000 claims description 2
- 230000005494 condensation Effects 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 claims description 2
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 22
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- 238000003756 stirring Methods 0.000 description 14
- 239000007787 solid Substances 0.000 description 12
- 206010003658 Atrial Fibrillation Diseases 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000001035 drying Methods 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- CPYXFLGEDJPTHF-UHFFFAOYSA-N 1-(1-amino-4-methoxycyclohexa-2,4-dien-1-yl)ethanone Chemical compound C(C)(=O)C1(CC=C(OC)C=C1)N CPYXFLGEDJPTHF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 238000000967 suction filtration Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000003810 ethyl acetate extraction Methods 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 206010003130 Arrhythmia supraventricular Diseases 0.000 description 1
- 206010003662 Atrial flutter Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- YDVNLQGCLLPHAH-UHFFFAOYSA-N dichloromethane;hydrate Chemical compound O.ClCCl YDVNLQGCLLPHAH-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- RCFKEIREOSXLET-UHFFFAOYSA-N disulfamide Chemical compound CC1=CC(Cl)=C(S(N)(=O)=O)C=C1S(N)(=O)=O RCFKEIREOSXLET-UHFFFAOYSA-N 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- QWVGKYWNOKOFNN-UHFFFAOYSA-N o-cresol Chemical compound CC1=CC=CC=C1O QWVGKYWNOKOFNN-UHFFFAOYSA-N 0.000 description 1
- BHAAPTBBJKJZER-UHFFFAOYSA-N p-anisidine Chemical compound COC1=CC=C(N)C=C1 BHAAPTBBJKJZER-UHFFFAOYSA-N 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010184543.5A CN101838252B (zh) | 2010-05-27 | 2010-05-27 | 2-正丁基-5-取代氨基苯并呋喃及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010184543.5A CN101838252B (zh) | 2010-05-27 | 2010-05-27 | 2-正丁基-5-取代氨基苯并呋喃及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101838252A true CN101838252A (zh) | 2010-09-22 |
CN101838252B CN101838252B (zh) | 2016-05-04 |
Family
ID=42741957
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201010184543.5A Active CN101838252B (zh) | 2010-05-27 | 2010-05-27 | 2-正丁基-5-取代氨基苯并呋喃及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101838252B (zh) |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102070579A (zh) * | 2011-01-19 | 2011-05-25 | 上海医药工业研究院 | 2-正丁基-3-(4-取代丙氧基苯甲酰基)-5-取代氨基苯并呋喃的制备方法 |
CN102070581A (zh) * | 2011-01-19 | 2011-05-25 | 上海医药工业研究院 | 2-正丁基-3-(4-(3-二正丁基氨基丙氧基)苯甲酰基)-5-氨基苯并呋喃的制备 |
CN102070577A (zh) * | 2011-01-19 | 2011-05-25 | 上海医药工业研究院 | 2-正丁基-3-(4-取代丙氧基苯甲酰基)-5-取代氨基苯并呋喃及其应用 |
CN102070578A (zh) * | 2011-01-19 | 2011-05-25 | 上海医药工业研究院 | 2-正丁基-3-(4-(3-二正丁基氨基丙氧基)苯甲酰基)-5-烷酰基氨基苯并呋喃的制备方法 |
CN102070580A (zh) * | 2011-01-19 | 2011-05-25 | 上海医药工业研究院 | 2-正丁基-3-(4-(3-二正丁基氨基丙氧基)苯甲酰基)-5-取代氨基苯并呋喃的制备 |
CN102153531A (zh) * | 2011-01-31 | 2011-08-17 | 金春华 | 一种用于制备决奈达隆的中间体及其制备方法 |
CN102180847A (zh) * | 2010-12-31 | 2011-09-14 | 江苏万全特创医药生物技术有限公司 | 一种决奈达隆新关键中间体的制备方法 |
CN102180848A (zh) * | 2010-12-31 | 2011-09-14 | 江苏万全特创医药生物技术有限公司 | 一种新型抗心律失常药决奈达隆的制备方法 |
CN102321057A (zh) * | 2011-06-02 | 2012-01-18 | 北京阳光诺和药物研究有限公司 | N-取代的甲磺酰基胺基-苯并呋喃衍生物、其制备方法及用途 |
WO2012010913A1 (en) * | 2010-07-22 | 2012-01-26 | Sanofi | Novel process for the preparation of dronedarone |
CN103450124A (zh) * | 2013-08-30 | 2013-12-18 | 江苏九九久科技股份有限公司 | 决奈达隆合成方法 |
CN103562195A (zh) * | 2011-03-29 | 2014-02-05 | 赛诺菲 | 通过n-丁基化制备决奈达隆的方法 |
CN103562196A (zh) * | 2011-03-29 | 2014-02-05 | 赛诺菲 | 使用胺中间体化合物制备决奈达隆的还原胺化方法 |
US9174958B2 (en) | 2010-06-18 | 2015-11-03 | Sanofi | Process for the preparation of dronedarone |
US9193703B2 (en) | 2011-03-29 | 2015-11-24 | Sanofi | Process for preparation of dronedarone by mesylation |
US9221778B2 (en) | 2012-02-13 | 2015-12-29 | Sanofi | Process for preparation of dronedarone by removal of hydroxyl group |
US9221777B2 (en) | 2012-01-20 | 2015-12-29 | Sanofi | Process for preparation of dronedarone by the use of dibutylaminopropanol reagent |
US9238636B2 (en) | 2012-05-31 | 2016-01-19 | Sanofi | Process for preparation of dronedarone by Grignard reaction |
US9249119B2 (en) | 2012-02-14 | 2016-02-02 | Sanofi | Process for the preparation of dronedarone by oxidation of a sulphenyl group |
US9334254B2 (en) | 2010-03-30 | 2016-05-10 | Sanofi | Process for preparing sulfonamidobenzofuran derivatives |
US9382223B2 (en) | 2012-02-22 | 2016-07-05 | Sanofi | Process for preparation of dronedarone by oxidation of a hydroxyl group |
US9499507B2 (en) | 2011-11-29 | 2016-11-22 | Sanofi | Method for preparing 5-amino-benzoyl-benzofuran derivatives |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994029317A1 (en) * | 1993-06-10 | 1994-12-22 | Merck & Co., Inc. | Process of making spirocycles and analogs thereof |
WO2002048132A1 (fr) * | 2000-12-11 | 2002-06-20 | Sanofi-Synthelabo | Derive de methanesulfonamido-benzofurane, son procede de preparation et son utilisation comme intermediaire de synthese |
WO2003040120A1 (en) * | 2001-11-08 | 2003-05-15 | Isp Investments Inc. | Process for the preparation of dronedarone |
US20060137207A1 (en) * | 2002-07-13 | 2006-06-29 | Caldwell Stuart T | Flavonoid compounds as therapeutic antioxidants |
CA2566166A1 (en) * | 2006-10-30 | 2008-04-30 | The University Of Melbourne | Improved flavonols |
CN101993427A (zh) * | 2009-08-26 | 2011-03-30 | 成都伊诺达博医药科技有限公司 | 一种制备决奈达隆(Dronedarone)的新方法 |
-
2010
- 2010-05-27 CN CN201010184543.5A patent/CN101838252B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994029317A1 (en) * | 1993-06-10 | 1994-12-22 | Merck & Co., Inc. | Process of making spirocycles and analogs thereof |
WO2002048132A1 (fr) * | 2000-12-11 | 2002-06-20 | Sanofi-Synthelabo | Derive de methanesulfonamido-benzofurane, son procede de preparation et son utilisation comme intermediaire de synthese |
WO2003040120A1 (en) * | 2001-11-08 | 2003-05-15 | Isp Investments Inc. | Process for the preparation of dronedarone |
US20060137207A1 (en) * | 2002-07-13 | 2006-06-29 | Caldwell Stuart T | Flavonoid compounds as therapeutic antioxidants |
CA2566166A1 (en) * | 2006-10-30 | 2008-04-30 | The University Of Melbourne | Improved flavonols |
CN101993427A (zh) * | 2009-08-26 | 2011-03-30 | 成都伊诺达博医药科技有限公司 | 一种制备决奈达隆(Dronedarone)的新方法 |
Non-Patent Citations (3)
Title |
---|
GREENE T.W.等: "胺基的保护", 《有机合成中的保护基》 * |
闻韧: "《药物合成反应》", 31 January 2003 * |
闻韧: "氨基的保护", 《药物合成反应 第二版》 * |
Cited By (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9334254B2 (en) | 2010-03-30 | 2016-05-10 | Sanofi | Process for preparing sulfonamidobenzofuran derivatives |
US9174958B2 (en) | 2010-06-18 | 2015-11-03 | Sanofi | Process for the preparation of dronedarone |
US8816103B2 (en) | 2010-07-22 | 2014-08-26 | Sanofi | Process for the preparation of dronedarone |
CN103228639A (zh) * | 2010-07-22 | 2013-07-31 | 赛诺菲 | 用于制备决奈达隆的新方法 |
WO2012010913A1 (en) * | 2010-07-22 | 2012-01-26 | Sanofi | Novel process for the preparation of dronedarone |
CN102180848A (zh) * | 2010-12-31 | 2011-09-14 | 江苏万全特创医药生物技术有限公司 | 一种新型抗心律失常药决奈达隆的制备方法 |
CN102180847A (zh) * | 2010-12-31 | 2011-09-14 | 江苏万全特创医药生物技术有限公司 | 一种决奈达隆新关键中间体的制备方法 |
CN102070580B (zh) * | 2011-01-19 | 2015-05-20 | 上海医药工业研究院 | 2-正丁基-3-(4-(3-二正丁基氨基丙氧基)苯甲酰基)-5-取代氨基苯并呋喃的制备 |
CN102070577A (zh) * | 2011-01-19 | 2011-05-25 | 上海医药工业研究院 | 2-正丁基-3-(4-取代丙氧基苯甲酰基)-5-取代氨基苯并呋喃及其应用 |
CN102070577B (zh) * | 2011-01-19 | 2016-03-09 | 上海医药工业研究院 | 2-正丁基-3-(4-取代丙氧基苯甲酰基)-5-取代氨基苯并呋喃及其应用 |
CN102070580A (zh) * | 2011-01-19 | 2011-05-25 | 上海医药工业研究院 | 2-正丁基-3-(4-(3-二正丁基氨基丙氧基)苯甲酰基)-5-取代氨基苯并呋喃的制备 |
CN102070581A (zh) * | 2011-01-19 | 2011-05-25 | 上海医药工业研究院 | 2-正丁基-3-(4-(3-二正丁基氨基丙氧基)苯甲酰基)-5-氨基苯并呋喃的制备 |
CN102070581B (zh) * | 2011-01-19 | 2015-11-25 | 上海医药工业研究院 | 2-正丁基-3-(4-(3-二正丁基氨基丙氧基)苯甲酰基)-5-氨基苯并呋喃的制备 |
CN102070579A (zh) * | 2011-01-19 | 2011-05-25 | 上海医药工业研究院 | 2-正丁基-3-(4-取代丙氧基苯甲酰基)-5-取代氨基苯并呋喃的制备方法 |
CN102070578A (zh) * | 2011-01-19 | 2011-05-25 | 上海医药工业研究院 | 2-正丁基-3-(4-(3-二正丁基氨基丙氧基)苯甲酰基)-5-烷酰基氨基苯并呋喃的制备方法 |
CN102070579B (zh) * | 2011-01-19 | 2016-03-09 | 上海医药工业研究院 | 2-正丁基-3-(4-取代丙氧基苯甲酰基)-5-取代氨基苯并呋喃的制备方法 |
CN102070578B (zh) * | 2011-01-19 | 2015-10-14 | 上海医药工业研究院 | 2-正丁基-3-(4-(3-二正丁基氨基丙氧基)苯甲酰基)-5-烷酰基氨基苯并呋喃的制备方法 |
CN102153531A (zh) * | 2011-01-31 | 2011-08-17 | 金春华 | 一种用于制备决奈达隆的中间体及其制备方法 |
CN103562196A (zh) * | 2011-03-29 | 2014-02-05 | 赛诺菲 | 使用胺中间体化合物制备决奈达隆的还原胺化方法 |
US9174959B2 (en) | 2011-03-29 | 2015-11-03 | Sanofi | Process for preparation of dronedarone by N-butylation |
US9193703B2 (en) | 2011-03-29 | 2015-11-24 | Sanofi | Process for preparation of dronedarone by mesylation |
CN103562195A (zh) * | 2011-03-29 | 2014-02-05 | 赛诺菲 | 通过n-丁基化制备决奈达隆的方法 |
US9611242B2 (en) | 2011-03-29 | 2017-04-04 | Sanofi | Process for preparation of dronedarone by N-butylation |
CN102321057A (zh) * | 2011-06-02 | 2012-01-18 | 北京阳光诺和药物研究有限公司 | N-取代的甲磺酰基胺基-苯并呋喃衍生物、其制备方法及用途 |
US9499507B2 (en) | 2011-11-29 | 2016-11-22 | Sanofi | Method for preparing 5-amino-benzoyl-benzofuran derivatives |
US9221777B2 (en) | 2012-01-20 | 2015-12-29 | Sanofi | Process for preparation of dronedarone by the use of dibutylaminopropanol reagent |
US9708281B2 (en) | 2012-01-20 | 2017-07-18 | Sanofi | Process for preparation of dronedarone by the use of dibutylaminopropanol reagent |
US9221778B2 (en) | 2012-02-13 | 2015-12-29 | Sanofi | Process for preparation of dronedarone by removal of hydroxyl group |
US9701654B2 (en) | 2012-02-13 | 2017-07-11 | Sanofi | Process for preparation of dronedarone by removal of hydroxyl group |
US9249119B2 (en) | 2012-02-14 | 2016-02-02 | Sanofi | Process for the preparation of dronedarone by oxidation of a sulphenyl group |
US9382223B2 (en) | 2012-02-22 | 2016-07-05 | Sanofi | Process for preparation of dronedarone by oxidation of a hydroxyl group |
US9238636B2 (en) | 2012-05-31 | 2016-01-19 | Sanofi | Process for preparation of dronedarone by Grignard reaction |
CN103450124B (zh) * | 2013-08-30 | 2016-03-09 | 江苏九九久科技股份有限公司 | 决奈达隆合成方法 |
CN103450124A (zh) * | 2013-08-30 | 2013-12-18 | 江苏九九久科技股份有限公司 | 决奈达隆合成方法 |
Also Published As
Publication number | Publication date |
---|---|
CN101838252B (zh) | 2016-05-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101838252A (zh) | 2-正丁基-5-取代氨基苯并呋喃及其制备方法 | |
CN103304547A (zh) | 一种抗抑郁药维拉唑酮的制备方法 | |
CN102746231A (zh) | 塞来昔布制备工艺 | |
CN109020881A (zh) | 一种阿帕替尼的制备方法 | |
WO2019019795A1 (zh) | 一种沙库必曲中间体的制备方法 | |
CN109206317B (zh) | 一种金刚烷胺类硝酸酯衍生物的制备工艺 | |
CN108047076B (zh) | 一种奥司他韦对映异构体的制备方法 | |
CN105837493B (zh) | 尼达尼布的合成方法及其中间体 | |
CN111333613A (zh) | 一种三氟甲基萘满酮类化合物制备方法 | |
CN102911128A (zh) | 一种缬沙坦的合成方法 | |
CN102993121A (zh) | 一种高纯度罗沙替丁醋酸酯盐酸盐的合成制备方法 | |
CN102229538B (zh) | 一种达泊西汀的合成方法 | |
CN105218445A (zh) | 一种络氨酸酶抑制剂Foretinib的制备方法 | |
CN103467445B (zh) | 苯甲酸阿格列汀的制备方法 | |
CN104016877A (zh) | 一种苯基乙酰胺类化合物及在制备米拉贝隆中的应用 | |
CN103408501B (zh) | 苄基嘧啶衍生物、其制备方法及其医药用途 | |
CN102180864B (zh) | 一种雷尼酸锶的制备方法 | |
CN108794375A (zh) | 一种帕比司他中间体及其合成与应用 | |
CN104086486B (zh) | 一种磷酸二甲啡烷的制备方法 | |
CN113429379A (zh) | 一种lh-1801中间体及其制备方法和应用 | |
CN105348197A (zh) | 一种盐酸绿卡色林的制备方法 | |
CN103848756B (zh) | 特立氟胺及其中间体的制备方法 | |
CN101475511B (zh) | 一种3,4-二甲氧基苯乙腈的合成方法 | |
CN104230909B (zh) | 一种阿齐沙坦的制备方法 | |
CN108218806A (zh) | 一种n-叔丁氧羰基吗啉-3-羧酸的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20161214 Address after: 570314 Nanhai Avenue, Hainan, Haikou, China, No. 279 Patentee after: AVENTIS PHARMA (HAINAN) Co.,Ltd. Address before: 100097 Beijing city Haidian District Sijiqing Wanquan Zhuang 3 Building Patentee before: Beijing D-Venture Pharmaceutical Technology Corp. |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: 2-Butyl-5-substituted amino benzofuran and its preparation method Granted publication date: 20160504 Pledgee: Sanya Rural Commercial Bank Co.,Ltd. Pledgor: AVENTIS PHARMA (HAINAN) Co.,Ltd. Registration number: Y2024980014810 |